Exelixis, Inc. revenue
Exelixis, Inc.'s revenue was $2.32bn in fiscal 2025, up 7.0% on the year before. Since fiscal 2009 ($152m) it has grown at a compound 18.6% a year. Over the last twelve months it was $2.50bn.
Revenue history
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Jan 2016 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Jan 2020 | 2020Jan 2021 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Jan 2025 | 2025Jan 2026 | LTMOct 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 152 | 185 | 290 | 47 | 31 | 25 | 37 | 191 | 452 | 854 | 968 | 988 | 1,435 | 1,611 | 1,830 | 2,169 | 2,320 | 2,497 |
| Growth on the year before | — | +21.9% | +56.5% | −83.6% | −34.0% | −19.9% | +48.0% | +415.0% | +136.3% | +88.7% | +13.3% | +2.0% | +45.3% | +12.3% | +13.6% | +18.5% | +7.0% | — |
| Gross profit | — | — | — | — | — | — | — | 185 | 437 | 827 | 935 | 951 | 1,382 | 1,553 | 1,758 | 2,092 | 2,236 | 2,404 |
| Gross margin | — | — | — | — | — | — | — | 96.6% | 96.7% | 96.9% | 96.6% | 96.3% | 96.3% | 96.4% | 96.0% | 96.5% | 96.4% | 96.3% |
Where the revenue comes from
| Line of business | Revenue | YoY |
|---|---|---|
| Product Gross | $3B | ▲ 19.6% |
| Products | $2.1B | ▲ 17.3% |
| Cabometyx | $2.1B | ▲ 17.5% |
| Licenses | $214M | ▼ 38.6% |
| Collaboration | $197M | ▼ 45.1% |
| Cometriq | $9.4M | ▼ 15.4% |
| Services | -$17.1M | ▼ 269.5% |
| Product Sales Discounts and Allowances | -$889M | — |
These categories overlap or exclude eliminations, so shares aren't shown.
| Region | Revenue | Share | YoY |
|---|---|---|---|
| United States | $2.1B | 92.3% | ▲ 17.4% |
| Europe | $154M | 6.6% | ▼ 51.6% |
| Japan | $25.6M | 1.1% | ▼ 5.5% |
From Exelixis, Inc.'s 10-K filed February 10, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Exelixis, Inc. | $2.50bn | 9.1% | 12.1% |
| Natera, Inc. | $2.71bn | 37.8% | 42.7% |
| Moderna | $2.23bn | -27.6% | -40.6% |
| United Therapeutics Corp | $3.15bn | 2.5% | 14.3% |
| Biontech SE | $3.24bn | 9.0% | — |
| Biomarin Pharmaceutical Inc | $3.41bn | 11.2% | 15.1% |
Compare with peers
- Natera, Inc. revenue
- Moderna revenue
- United Therapeutics Corp revenue
- Biontech SE revenue
- Biomarin Pharmaceutical Inc revenue
Head to head: EXEL vs NTRAEXEL vs MRNAEXEL vs UTHR
More: Biotechnology stocks compared, Health Care sector, rankings of US companies